An investigational oral small molecule designed to modify RNA splicing of the HTT transcript to lower mutant huntingtin production, similar in concept to votoplam/PTC518 but from a different chemical series. Recently advanced into a Phase II/III trial (FALCON-HD).
Dosing Notes
Investigational; oral dosing under evaluation in FALCON-HD.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
Low ConfidenceBased on case reports, expert opinion, or early-phase data only
SKY-0515 recently advanced into the Phase II/III FALCON-HD trial; as an early-stage program, efficacy and safety data in humans are still limited.
Verified Jul 2026
Peer Reviewed
Huntington's disease clinical trials update: October 2025 (Journal of Huntington's Disease)